Coronavirus: Medical Treatments

Department of Health and Social Care written question – answered on 27th September 2022.

Alert me about debates like this

Photo of Andrew Gwynne Andrew Gwynne Shadow Minister (Health and Social Care)

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.

Photo of Robert Jenrick Robert Jenrick Minister of State (Department of Health and Social Care)

RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.

We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.